Acquired haemophilia is a potentially life‐threatening bleeding disorder caused by the
development of autoantibodies against coagulation factors, most commonly against factor …

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor)
to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe …

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII).
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …

Autoantibodies affecting the activity or accelerating the clearance of clotting factors
(acquired inhibitors) can develop in patients with autoimmune or malignant disorders, but …

Factor VIII inhibitor bypass activity (FEIBA) is a recommended first‐line bypassing agent for
bleeding episodes in patients with acquired haemophilia A (AHA). Due to the low incidence …

Despite anti-haemorrhagic therapy with proper doses of activated prothrombin complex
concentrate (aPCC, Feiba®), patients with acquired haemophilia A (AHA) have a …

La hemofilia adquirida es una enfermedad de muy poco frecuente presentación. El paciente
habitualmente consulta con equimosis y hematomas extensos en la piel y tejido celular …

Acquired haemophilia A (AHA) is caused by autoantibody inhibitors of coagulation factor VIII
(FVIII: C). Recent onset of bleeds and isolated prolongation of the activated partial …

The hemostatic balance changes with advancing age which may be due to factors such as
platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic …

Acquired haemophilia (AH) is a rare, often severe bleeding disorder characterised by
autoantibodies to coagulation factor VIII (FVIII). Observational studies offer crucial insight …